Protara Therapeutics (TARA) Net Income towards Common Stockholders (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Net Income towards Common Stockholders of -$28.9 million for Q1 2026, down 58.4% year-over-year from -$69.5 million in Q1 2025, and down 48.42% quarter-over-quarter from -$19.5 million in Q4 2025.
Powered by 
Analysis
Protara Therapeutics (TARA) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Net Income towards Common Stockholders for 14 consecutive years, with -$28.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 58.4% year-over-year to -$28.9 million; the TTM figure through Mar 2026 stood at -$88.8 million (down 52.32% YoY), while the FY2025 annual figure was -$148.1 million, down 25.13% from the prior year.
- Net Income towards Common Stockholders eased to -$28.9 million in Q1 2026 per TARA's latest filing, from -$19.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $10.8 million in Q1 2022 and bottomed at -$39.0 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged -$15.8 million across 5 years, with a median of -$17.7 million in 2024.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 178.25% — and 2024, when it sank 270.9%.
- Protara Therapeutics' Net Income towards Common Stockholders stood at -$39.0 million in 2022, then surged by 73.77% to -$10.2 million in 2023, then decreased by 11.32% to -$11.4 million in 2024, then tumbled by 71.29% to -$19.5 million in 2025, then slumped by 48.42% to -$28.9 million in 2026.
- Business Quant data shows TARA's Net Income towards Common Stockholders at -$28.9 million in Q1 2026, -$19.5 million in Q4 2025, and -$19.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Protara Therapeutics | 241.28 Mn | 241.28 Mn | - | -21.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -21.67 Mn |
| Mar 31, 2026 | -17.78 Mn |
| Dec 31, 2025 | -17.56 Mn |
| Sep 30, 2025 | -13.26 Mn |
| Jun 30, 2025 | -14.96 Mn |
| Mar 31, 2025 | -12.40 Mn |
| Dec 31, 2024 | -13.16 Mn |
| Sep 30, 2024 | -11.22 Mn |
| Jun 30, 2024 | -9.51 Mn |
| Mar 31, 2024 | -11.10 Mn |
| Dec 31, 2023 | -10.22 Mn |
| Sep 30, 2023 | -9.86 Mn |
| Jun 30, 2023 | -29.38 Mn |
| Mar 31, 2023 | 9.05 Mn |
| Dec 31, 2022 | -38.97 Mn |
| Sep 30, 2022 | -7.69 Mn |
| Jun 30, 2022 | -30.05 Mn |
| Mar 31, 2022 | 10.76 Mn |
| Dec 31, 2021 | -10.23 Mn |
| Sep 30, 2021 | -10.77 Mn |